Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 793 to 800 of 800 entries
Sorted by: Best Match Show Resources per page
Antiretroviral Drugs Regulate Epigenetic Modification of Cardiac Cells Through Modulation of H3K9 and H3K27 Acetylation.

Frontiers in cardiovascular medicine

Kashyap S, Mukker A, Gupta D, Datta PK, Rappaport J, Jacobson JM, Ebert SN, Gupta MK.
PMID: 33898535
Front Cardiovasc Med. 2021 Apr 09;8:634774. doi: 10.3389/fcvm.2021.634774. eCollection 2021.

Antiretroviral therapy (ART) has significantly reduced the rate of mortality in HIV infected population, but people living with HIV (PLWH) show higher rates of cardiovascular disease (CVD). However, the effect of antiretroviral (ARV) drug treatment on cardiac cells is...

Cite
Kashyap S, Mukker A, Gupta D, et al. Antiretroviral Drugs Regulate Epigenetic Modification of Cardiac Cells Through Modulation of H3K9 and H3K27 Acetylation. Front Cardiovasc Med. 2021;8:634774doi: 10.3389/fcvm.2021.634774.
Kashyap, S., Mukker, A., Gupta, D., Datta, P. K., Rappaport, J., Jacobson, J. M., Ebert, S. N., & Gupta, M. K. (2021). Antiretroviral Drugs Regulate Epigenetic Modification of Cardiac Cells Through Modulation of H3K9 and H3K27 Acetylation. Frontiers in cardiovascular medicine, 8634774. https://doi.org/10.3389/fcvm.2021.634774
Kashyap, Shiridhar, et al. "Antiretroviral Drugs Regulate Epigenetic Modification of Cardiac Cells Through Modulation of H3K9 and H3K27 Acetylation." Frontiers in cardiovascular medicine vol. 8 (2021): 634774. doi: https://doi.org/10.3389/fcvm.2021.634774
Kashyap S, Mukker A, Gupta D, Datta PK, Rappaport J, Jacobson JM, Ebert SN, Gupta MK. Antiretroviral Drugs Regulate Epigenetic Modification of Cardiac Cells Through Modulation of H3K9 and H3K27 Acetylation. Front Cardiovasc Med. 2021 Apr 09;8:634774. doi: 10.3389/fcvm.2021.634774. eCollection 2021. PMID: 33898535; PMCID: PMC8062764.
Copy Download .nbib Format: NLM
High Levels of Soluble Programmed Death-1 Are Associated with Virological Response in Chronic Hepatitis B patients after Antiviral Treatment.

Virus research

Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X.
PMID: 34929214
Virus Res. 2021 Dec 18;198660. doi: 10.1016/j.virusres.2021.198660. Epub 2021 Dec 18.

BACKGROUND: Soluble programmed cell death protein-1 (sPD-1) plays an important role in chronic hepatitis B virus (HBV) infection by counteracting the inhibitory effect of programmed death ligand-1 (PD-L1) on immune cells. Here, we investigated the ability of sPD-1 to...

Cite
Tan N, Luo H, Kang Q, et al. High Levels of Soluble Programmed Death-1 Are Associated with Virological Response in Chronic Hepatitis B patients after Antiviral Treatment. Virus Res. 2021;198660doi: 10.1016/j.virusres.2021.198660.
Tan, N., Luo, H., Kang, Q., Pan, J., Cheng, R., Xi, H., Chen, H., Han, Y., Yang, Y., & Xu, X. (2021). High Levels of Soluble Programmed Death-1 Are Associated with Virological Response in Chronic Hepatitis B patients after Antiviral Treatment. Virus research, 198660. https://doi.org/10.1016/j.virusres.2021.198660
Tan, Ning, et al. "High Levels of Soluble Programmed Death-1 Are Associated with Virological Response in Chronic Hepatitis B patients after Antiviral Treatment." Virus research vol. (2021): 198660. doi: https://doi.org/10.1016/j.virusres.2021.198660
Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High Levels of Soluble Programmed Death-1 Are Associated with Virological Response in Chronic Hepatitis B patients after Antiviral Treatment. Virus Res. 2021 Dec 18;198660. doi: 10.1016/j.virusres.2021.198660. Epub 2021 Dec 18. PMID: 34929214.
Copy Download .nbib Format: NLM
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era.

Diagnostics (Basel, Switzerland)

Cento V, Perno CF.
PMID: 33947009
Diagnostics (Basel). 2021 Apr 29;11(5). doi: 10.3390/diagnostics11050809.

The diagnostic and therapeutic management of the Coronavirus Disease 2019 (COVID-19) pandemic in the HIV population brought some known criticalities (and opportunities) to the forefront, for both those who are facing their first therapeutic line today, and for those...

Cite
Cento V, Perno CF. Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era. Diagnostics (Basel). 2021;11(5)doi: 10.3390/diagnostics11050809.
Cento, V., & Perno, C. F. (2021). Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era. Diagnostics (Basel, Switzerland), 11(5), . https://doi.org/10.3390/diagnostics11050809
Cento, Valeria, and Perno, Carlo Federico. "Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era." Diagnostics (Basel, Switzerland) vol. 11,5 (2021). doi: https://doi.org/10.3390/diagnostics11050809
Cento V, Perno CF. Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era. Diagnostics (Basel). 2021 Apr 29;11(5). doi: 10.3390/diagnostics11050809. PMID: 33947009; PMCID: PMC8145545.
Copy Download .nbib Format: NLM
Successful Use of Multidisciplinary Palliative Care in the Outpatient Treatment of Disseminated Histoplasmosis in an HIV Positive Child.

Children (Basel, Switzerland)

Lopez A, Bacha J, Kovarik C, Campbell L.
PMID: 33918245
Children (Basel). 2021 Apr 02;8(4). doi: 10.3390/children8040273.

Histoplasmosis is an uncommon opportunistic infection in human immunodeficiency virus (HIV) positive children. The most common form is primary disseminated histoplasmosis, characterized by persistent fever and failure to thrive. A 10-year-old HIV positive girl presented to the Baylor College...

Cite
Lopez A, Bacha J, Kovarik C, et al. Successful Use of Multidisciplinary Palliative Care in the Outpatient Treatment of Disseminated Histoplasmosis in an HIV Positive Child. Children (Basel). 2021;8(4)doi: 10.3390/children8040273.
Lopez, A., Bacha, J., Kovarik, C., & Campbell, L. (2021). Successful Use of Multidisciplinary Palliative Care in the Outpatient Treatment of Disseminated Histoplasmosis in an HIV Positive Child. Children (Basel, Switzerland), 8(4), . https://doi.org/10.3390/children8040273
Lopez, Alison, et al. "Successful Use of Multidisciplinary Palliative Care in the Outpatient Treatment of Disseminated Histoplasmosis in an HIV Positive Child." Children (Basel, Switzerland) vol. 8,4 (2021). doi: https://doi.org/10.3390/children8040273
Lopez A, Bacha J, Kovarik C, Campbell L. Successful Use of Multidisciplinary Palliative Care in the Outpatient Treatment of Disseminated Histoplasmosis in an HIV Positive Child. Children (Basel). 2021 Apr 02;8(4). doi: 10.3390/children8040273. PMID: 33918245; PMCID: PMC8065956.
Copy Download .nbib Format: NLM
A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C.

Antimicrobial agents and chemotherapy

Boyer PL, Rehm CA, Sneller MC, Mican J, Caplan MR, Dewar R, Ferris AL, Clark P, Johnson A, Maldarelli F, Hughes SH.
PMID: 34723625
Antimicrob Agents Chemother. 2021 Nov 01;AAC0150021. doi: 10.1128/AAC.01500-21. Epub 2021 Nov 01.

Resistance to anti-Human Immunodeficiency Virus (HIV) drugs has been a problem from the beginning of antiviral drug treatments. The recent expansion of combination antiretroviral therapy worldwide has led to an increase in resistance to antiretrovirals; understanding the mechanisms of...

Cite
Boyer PL, Rehm CA, Sneller MC, et al. A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C. Antimicrob Agents Chemother. 2021;AAC0150021doi: 10.1128/AAC.01500-21.
Boyer, P. L., Rehm, C. A., Sneller, M. C., Mican, J., Caplan, M. R., Dewar, R., Ferris, A. L., Clark, P., Johnson, A., Maldarelli, F., & Hughes, S. H. (2021). A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C. Antimicrobial agents and chemotherapy, AAC0150021. https://doi.org/10.1128/AAC.01500-21
Boyer, Paul L, et al. "A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C." Antimicrobial agents and chemotherapy vol. (2021): AAC0150021. doi: https://doi.org/10.1128/AAC.01500-21
Boyer PL, Rehm CA, Sneller MC, Mican J, Caplan MR, Dewar R, Ferris AL, Clark P, Johnson A, Maldarelli F, Hughes SH. A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C. Antimicrob Agents Chemother. 2021 Nov 01;AAC0150021. doi: 10.1128/AAC.01500-21. Epub 2021 Nov 01. PMID: 34723625.
Copy Download .nbib Format: NLM
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).

AIDS research and therapy

Kumar PN, Salvato P, LaMarca A, DeJesus E, Patel P, McClernon D, Florance A, Shaefer MS.
PMID: 19358725
AIDS Res Ther. 2009 Apr 09;6:3. doi: 10.1186/1742-6405-6-3.

BACKGROUND: Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with certain co-morbidities, women of child-bearing potential, and intolerability to components of...

Cite
Kumar PN, Salvato P, LaMarca A, et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther. 2009;6:3doi: 10.1186/1742-6405-6-3.
Kumar, P. N., Salvato, P., LaMarca, A., DeJesus, E., Patel, P., McClernon, D., Florance, A., & Shaefer, M. S. (2009). A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS research and therapy, 63. https://doi.org/10.1186/1742-6405-6-3
Kumar, Princy N, et al. "A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)." AIDS research and therapy vol. 6 (2009): 3. doi: https://doi.org/10.1186/1742-6405-6-3
Kumar PN, Salvato P, LaMarca A, DeJesus E, Patel P, McClernon D, Florance A, Shaefer MS. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther. 2009 Apr 09;6:3. doi: 10.1186/1742-6405-6-3. PMID: 19358725; PMCID: PMC2672933.
Copy Download .nbib Format: NLM
Antiretroviral Prophylaxis: A Digestive Complication to Know.

Pediatric emergency care

Lemoine A, Michot J, Viala J, Tounian P, Dollfus C.
PMID: 32118832
Pediatr Emerg Care. 2021 Dec 01;37(12):e1745-e1746. doi: 10.1097/PEC.0000000000001952.

ABSTRACT: An 8-year-old child experienced abdominal pain and melena due to duodenal and ileal ulcerations throughout antiretroviral prophylactic treatment after a needlestick injury. Mild to moderate adverse effects often occur with lamivudine and zidovudine, but more severe adverse effects...

Cite
Lemoine A, Michot J, Viala J, et al. Antiretroviral Prophylaxis: A Digestive Complication to Know. Pediatr Emerg Care. 2021;37(12):e1745-e1746doi: 10.1097/PEC.0000000000001952.
Lemoine, A., Michot, J., Viala, J., Tounian, P., & Dollfus, C. (2021). Antiretroviral Prophylaxis: A Digestive Complication to Know. Pediatric emergency care, 37(12), e1745-e1746. https://doi.org/10.1097/PEC.0000000000001952
Lemoine, Anaïs, et al. "Antiretroviral Prophylaxis: A Digestive Complication to Know." Pediatric emergency care vol. 37,12 (2021): e1745-e1746. doi: https://doi.org/10.1097/PEC.0000000000001952
Lemoine A, Michot J, Viala J, Tounian P, Dollfus C. Antiretroviral Prophylaxis: A Digestive Complication to Know. Pediatr Emerg Care. 2021 Dec 01;37(12):e1745-e1746. doi: 10.1097/PEC.0000000000001952. PMID: 32118832.
Copy Download .nbib Format: NLM
Amplifying anti-flooding electrode to fabricate modular electro-fenton system for degradation of antiviral drug lamivudine in wastewater.

Journal of hazardous materials

An J, Feng Y, Wang N, Zhao Q, Wang X, Li N.
PMID: 35032957
J Hazard Mater. 2021 Dec 30;428:128185. doi: 10.1016/j.jhazmat.2021.128185. Epub 2021 Dec 30.

The advanced oxidation based on in-situ hydrogen peroxide production using carbon air cathode is very potential for wastewater treatment. However, catalyst flooding and complex assembly patterns are the bottleneck limiting the air cathode to the long-term and large-scale application....

Cite
An J, Feng Y, Wang N, et al. Amplifying anti-flooding electrode to fabricate modular electro-fenton system for degradation of antiviral drug lamivudine in wastewater. J Hazard Mater. 2021;428:128185doi: 10.1016/j.jhazmat.2021.128185.
An, J., Feng, Y., Wang, N., Zhao, Q., Wang, X., & Li, N. (2021). Amplifying anti-flooding electrode to fabricate modular electro-fenton system for degradation of antiviral drug lamivudine in wastewater. Journal of hazardous materials, 428128185. https://doi.org/10.1016/j.jhazmat.2021.128185
An, Jingkun, et al. "Amplifying anti-flooding electrode to fabricate modular electro-fenton system for degradation of antiviral drug lamivudine in wastewater." Journal of hazardous materials vol. 428 (2021): 128185. doi: https://doi.org/10.1016/j.jhazmat.2021.128185
An J, Feng Y, Wang N, Zhao Q, Wang X, Li N. Amplifying anti-flooding electrode to fabricate modular electro-fenton system for degradation of antiviral drug lamivudine in wastewater. J Hazard Mater. 2021 Dec 30;428:128185. doi: 10.1016/j.jhazmat.2021.128185. Epub 2021 Dec 30. PMID: 35032957.
Copy Download .nbib Format: NLM
Showing 793 to 800 of 800 entries